Oumar Sano
Family · Reading, PANPI 1770912123
Payments from drug & device makers
Across 95 payments — averaging $42.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$439
- AbbVie$420
- E.r. Squibb & Sons, L.L.C.$413
- Alkermes, Inc.$406
- Novo Nordisk$285
- Medtronic$278
- plus $2K from 18 others
What the payments were for
- Food & beverage$3,97799%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $439 |
| AbbVie | 10 | $420 |
| E.r. Squibb & Sons, L.L.C. | 4 | $413 |
| Alkermes, Inc. | 6 | $406 |
| Novo Nordisk | 13 | $285 |
| Medtronic | 11 | $278 |
| Neurocrine Biosciences, Inc. | 2 | $220 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $209 |
| AstraZeneca | 6 | $193 |
| Lilly USA, LLC | 10 | $151 |
| Sanofi-aventis U.S. LLC | 2 | $135 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $124 |
| Boehringer Ingelheim | 6 | $115 |
| Braeburn Inc. | 1 | $107 |
| Vanda Pharmaceuticals Inc. | 1 | $101 |
| Bayer | 4 | $68 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $67 |
| Pfizer | 3 | $50 |
| Indivior Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| GSK | 1 | $18 |
| Merck | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$951
- COBENFY$381
- VRAYLAR$250
- REXULTI$220
- INGREZZA$125
- ABILIFY MAINTENA$125
- ABILIFY ASIMTUFII$125
- Austedo XR$125
- SOLIQUA 100/33$125
- BREZTRI$125
- Auvelity$124
- CAPLYTA$110
- BRIXADI$107
- Fanapt$101
How this compares
$4,002 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 114 | $94,677 |
| FarxigaDapagliflozin Propanediol | 89 | $65,555 |
| TrulicityDulaglutide | 45 | $49,143 |
| VivitrolNaltrexone Microspheres | 28 | $45,006 |
| OzempicSemaglutide | 32 | $32,477 |
| EliquisApixaban | 12 | $18,917 |
| MounjaroTirzepatide | 18 | $18,916 |
| JanuviaSitagliptin Phosphate | 26 | $18,002 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $15,142 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $12,319 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 85 | $10,859 |
| LinzessLinaclotide | 15 | $8,953 |
| MyrbetriqMirabegron | 16 | $7,349 |
| Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid | 21 | $6,369 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 36 | $5,980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $115 | $94,677114 claims |
| AstraZenecaFarxiga, Symbicort | $193 | $70,898104 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $151 | $68,05963 claims |
| Alkermes, Inc.Vivitrol | $406 | $45,00628 claims |
| MerckJanuvia, Janumet | $16 | $33,14447 claims |
| Novo NordiskOzempic | $285 | $32,47732 claims |
| PfizerEliquis | $50 | $18,91712 claims |
| GSKBreo Ellipta | $18 | $12,31929 claims |
| AbbVieLinzess | $420 | $8,95315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.
Other family in Reading
- Waylon SteeleReading$15K
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.